[Transplantation and osteoporosis].
Tanaka
Yoshiya
Y
The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health.
D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use; D005938:Glucocorticoids / Q000009:adverse effects; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D016377:Organ Transplantation / Q000009:adverse effects*; D010024:Osteoporosis / Q000188:drug therapy* / Q000209:etiology*; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride